Context Therapeutics is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies (TCEs) to treat solid tumors by engaging a patient's own T cells to attack cancer cells that express specific tumor-associated antigens. The company is advancing three primary product candidates targeting distinct tumor antigens—CLDN6, mesothelin, and Nectin-4—each of which is overexpressed across multiple cancer types with substantial patient populations. Context Therapeutics generates no revenue currently but retains full development and commercialization rights to its product candidates while establishing partnerships with established biotech companies, planning to commercialize its therapies independently or through strategic partnerships.